The Importance of First-Length Therapy

The most important driver for what I choose for first-length therapy is what the patient wants. It's not IgM myeloma. It's absolutely lymphoplasmicidic lymphoma. Can we do this mutation analysis from the referral blood? It's possible, but the sensitivity is much less. But again, you know, you need a certain dose of cells.